108 related articles for article (PubMed ID: 24583837)
41. Biologic therapies in colorectal cancer: indications and contraindications.
Fakih M
Am Soc Clin Oncol Educ Book; 2015; ():e197-206. PubMed ID: 25993173
[TBL] [Abstract][Full Text] [Related]
42. Biology and clinical management challenges in meningioma.
Mawrin C; Chung C; Preusser M
Am Soc Clin Oncol Educ Book; 2015; ():e106-15. PubMed ID: 25993161
[TBL] [Abstract][Full Text] [Related]
43. Systemic treatment: maintenance compared with holiday.
Punt CJ; Simkens LH; Koopman M
Am Soc Clin Oncol Educ Book; 2015; ():85-90. PubMed ID: 25993146
[TBL] [Abstract][Full Text] [Related]
44. Dose-finding study of hepatic arterial infusion of irinotecan-based treatment in patients with advanced cancers metastatic to the liver.
Said R; Kurzrock R; Naing A; Hong DS; Fu S; Piha-Paul SA; Wheler JJ; Janku F; Kee BK; Bidyasar S; Lim J; Wallace M; Tsimberidou AM
Invest New Drugs; 2015 Aug; 33(4):911-20. PubMed ID: 25990659
[TBL] [Abstract][Full Text] [Related]
45. Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations.
Masuda T; Imai H; Kuwako T; Miura Y; Yoshino R; Kaira K; Shimizu K; Sunaga N; Tomizawa Y; Ishihara S; Mogi A; Hisada T; Minato K; Takise A; Saito R; Yamada M
Clin Transl Oncol; 2015 Sep; 17(9):702-9. PubMed ID: 25990507
[TBL] [Abstract][Full Text] [Related]
46. Immune targeting in breast cancer.
Cimino-Mathews A; Foote JB; Emens LA
Oncology (Williston Park); 2015 May; 29(5):375-85. PubMed ID: 25979549
[TBL] [Abstract][Full Text] [Related]
47. Adverse radiation effect after stereotactic radiosurgery for brain metastases: incidence, time course, and risk factors.
Sneed PK; Mendez J; Vemer-van den Hoek JG; Seymour ZA; Ma L; Molinaro AM; Fogh SE; Nakamura JL; McDermott MW
J Neurosurg; 2015 Aug; 123(2):373-86. PubMed ID: 25978710
[TBL] [Abstract][Full Text] [Related]
48. The EML4-ALK oncogene: targeting an essential growth driver in human cancer.
Mano H
Proc Jpn Acad Ser B Phys Biol Sci; 2015; 91(5):193-201. PubMed ID: 25971657
[TBL] [Abstract][Full Text] [Related]
49. Post-treatment imaging of high-grade gliomas.
Sanghvi D
Indian J Radiol Imaging; 2015; 25(2):102-8. PubMed ID: 25969633
[TBL] [Abstract][Full Text] [Related]
50. PD-L1 inhibition with MPDL3280A for solid tumors.
Cha E; Wallin J; Kowanetz M
Semin Oncol; 2015 Jun; 42(3):484-7. PubMed ID: 25965367
[TBL] [Abstract][Full Text] [Related]
51. Targeted Therapy for NSCLC--A Double-edged Sword?
Dempke WC
Anticancer Res; 2015 May; 35(5):2503-12. PubMed ID: 25964523
[TBL] [Abstract][Full Text] [Related]
52. Capillary electrophoresis for rapid identification of monoclonal antibodies for routine application in hospital.
Jaccoulet E; Smadja C; Prognon P; Taverna M
Electrophoresis; 2015 Sep; 36(17):2050-6. PubMed ID: 25964136
[TBL] [Abstract][Full Text] [Related]
53. The prognostic significance of PD-L1 in bladder cancer.
Huang Y; Zhang SD; McCrudden C; Chan KW; Lin Y; Kwok HF
Oncol Rep; 2015 Jun; 33(6):3075-84. PubMed ID: 25963805
[TBL] [Abstract][Full Text] [Related]
54. Targeted therapies for treatment of renal cell carcinoma: recent advances and future perspectives.
Minguet J; Smith KH; Bramlage CP; Bramlage P
Cancer Chemother Pharmacol; 2015 Aug; 76(2):219-33. PubMed ID: 25963382
[TBL] [Abstract][Full Text] [Related]
55. Weighing up the benefits and harms of a new anti-cancer drug: a survey of Australian oncologists.
Chim L; Salkeld G; Stockler MR; Mileshkin L
Intern Med J; 2015 Aug; 45(8):834-42. PubMed ID: 25950615
[TBL] [Abstract][Full Text] [Related]
56. The role of anti-angiogenesis in non-small-cell lung cancer: an update.
Villaruz LC; Socinski MA
Curr Oncol Rep; 2015 Jun; 17(6):26. PubMed ID: 25947099
[TBL] [Abstract][Full Text] [Related]
57. French multicentric validation of ALK rearrangement diagnostic in 547 lung adenocarcinomas.
Lantuejoul S; Rouquette I; Blons H; Le Stang N; Ilie M; Begueret H; Grégoire V; Hofman P; Gros A; Garcia S; Monhoven N; Devouassoux-Shisheboran M; Mansuet-Lupo A; Thivolet F; Antoine M; Vignaud JM; Penault-Llorca F; Galateau-Sallé F; McLeer-Florin A
Eur Respir J; 2015 Jul; 46(1):207-18. PubMed ID: 25929957
[TBL] [Abstract][Full Text] [Related]
58. Use and impact of intermittent versus continuous systemic treatment strategies in metastatic colorectal cancer in routine practice.
Kay A; Yun L; Taback N; Krzyzanowska MK
Cancer; 2015 Aug; 121(16):2791-8. PubMed ID: 25925709
[TBL] [Abstract][Full Text] [Related]
59. Renal Toxicities of Targeted Therapies.
Abbas A; Mirza MM; Ganti AK; Tendulkar K
Target Oncol; 2015 Dec; 10(4):487-99. PubMed ID: 25922090
[TBL] [Abstract][Full Text] [Related]
60. Personalizing colon cancer adjuvant therapy: selecting optimal treatments for individual patients.
Dienstmann R; Salazar R; Tabernero J
J Clin Oncol; 2015 Jun; 33(16):1787-96. PubMed ID: 25918287
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
